Improved Detection Criteria for Detecting Drug-Drug Interaction Signals Using the Proportional Reporting Ratio

被引:11
|
作者
Noguchi, Yoshihiro [1 ]
Aoyama, Keisuke [1 ]
Kubo, Satoaki [1 ]
Tachi, Tomoya [1 ]
Teramachi, Hitomi [1 ,2 ]
机构
[1] Gifu Pharmaceut Univ, Lab Clin Pharm, 1-25-4 Daigakunishi, Gifu, Gifu 5011196, Japan
[2] Gifu Pharmaceut Univ, Lab Community Hlth Pharm, Gifu, Gifu 5011196, Japan
关键词
spontaneous reporting systems; drug-drug interaction; proportional reporting ratio; combination risk ratio; concomitant signal score;
D O I
10.3390/ph14010004
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
There is a current demand for "safety signal" screening, not only for single drugs but also for drug-drug interactions. The detection of drug-drug interaction signals using the proportional reporting ratio (PRR) has been reported, such as through using the combination risk ratio (CRR). However, the CRR does not consider the overlap between the lower limit of the 95% confidence interval of the PRR of concomitant-use drugs and the upper limit of the 95% confidence interval of the PRR of single drugs. In this study, we proposed the concomitant signal score (CSS), with the improved detection criteria, to overcome the issues associated with the CRR. "Hypothetical" true data were generated through a combination of signals detected using three detection algorithms. The signal detection accuracy of the analytical model under investigation was verified using machine learning indicators. The CSS presented improved signal detection when the number of reports was >= 3, with respect to the following metrics: accuracy (CRR: 0.752 -> CSS: 0.817), Youden's index (CRR: 0.555 -> CSS: 0.661), and F-measure (CRR: 0.780 -> CSS: 0.820). The proposed model significantly improved the accuracy of signal detection for drug-drug interactions using the PRR.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [31] Quantitative prediction of the extent of drug-drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes
    Iwasaki, Shinji
    Hirabayashi, Hideki
    Amano, Nobuyuki
    XENOBIOTICA, 2018, 48 (08) : 770 - 780
  • [32] Single concentration loss of activity assay provides an improved assessment of drug-drug interaction risk compared to IC50-shift
    Wong, Simon G.
    Lee, Mey
    Wong, Bradley K.
    XENOBIOTICA, 2016, 46 (11) : 953 - 966
  • [33] DeConDFFuse : Predicting drug-drug interaction using joint deep convolutional transform learning and decision forest fusion framework
    Gupta, Pooja
    Majumdar, Angshul
    Chouzenoux, Emilie
    Chierchia, Giovanni
    EXPERT SYSTEMS WITH APPLICATIONS, 2023, 227
  • [34] Evaluation of the Clinical Drug-Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach
    de Vries, Michiel
    Bonsmann, Susanne
    Pausch, Joerg
    Sumner, Melanie
    Birkmann, Alexander
    Zimmermann, Holger
    Kropeit, Dirk
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (07): : 755 - 769
  • [35] Propensity score-adjusted three-component mixture model for drug-drug interaction data mining in FDA Adverse Event Reporting System
    Wang, Xueying
    Li, Lang
    Wang, Lei
    Feng, Weixing
    Zhang, Pengyue
    STATISTICS IN MEDICINE, 2020, 39 (07) : 996 - 1010
  • [36] Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model
    Rioux, Nathalie
    Bellavance, Edith
    Bourg, Serge
    Garneau, Michel
    Ribadeneira, Maria D.
    Duan, Jianmin
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (07) : 396 - 401
  • [37] Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study
    van der Meer, Renske
    Wilms, Erik B.
    Eggermont, Margot N.
    Paalvast, Helena M.
    van Luin, Matthijs
    van Rossen, Richard C. J. M.
    Heijerman, Harry G. M.
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (03) : 549 - 553
  • [38] Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models
    Ryu, Hyo-jeong
    Moon, Hyun-ki
    Lee, Junho
    Yang, Gi-hyeok
    Yang, Sung-yoon
    Yun, Hwi-yeol
    Chae, Jung-woo
    Kang, Won-ho
    PHARMACEUTICALS, 2021, 14 (07)
  • [39] Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model
    Lin, Wen
    Ji, Tao
    Einolf, Heidi
    Ayalasomayajula, Surya
    Lin, Tsu-Han
    Hanna, Imad
    Heimbach, Tycho
    Breen, Christopher
    Jarugula, Venkateswar
    He, Handan
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (05) : 1439 - 1451
  • [40] Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin
    Park, Min-Ho
    Shin, Seok-Ho
    Byeon, Jin-Ju
    Lee, Gwan-Ho
    Yu, Byung-Yong
    Shin, Young G.
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2017, 21 (01): : 107 - 115